Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients.

Autor: Pérez-Isidro A; Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain., Xipell M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Nephrology and Renal Transplantation, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.; Reference Centre for Complex Glomerular Disease (CSUR) of the Spanish Health System, 08036 Barcelona, Spain., Llobell A; Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain., De Moner N; Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, 08036 Barcelona, Spain., Lledó GM; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.; Reference Centre for Systemic Autoimmune Diseases (CSUR) of the Spanish Health System, 08036 Barcelona, Spain., Cervera R; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.; Reference Centre for Systemic Autoimmune Diseases (CSUR) of the Spanish Health System, 08036 Barcelona, Spain., Prieto-González S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.; Reference Centre for Systemic Autoimmune Diseases (CSUR) of the Spanish Health System, 08036 Barcelona, Spain., Quintana LF; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Nephrology and Renal Transplantation, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.; Reference Centre for Complex Glomerular Disease (CSUR) of the Spanish Health System, 08036 Barcelona, Spain., Espinosa G; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain.; Reference Centre for Systemic Autoimmune Diseases (CSUR) of the Spanish Health System, 08036 Barcelona, Spain., García-Ormaechea M; Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, 08036 Barcelona, Spain.; Lime Tree Surgery NHS, Worthing BN14 0DL, UK., Ruiz-Ortiz E; Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain., Viñas O; Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, 08036 Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2023 Feb 06; Vol. 12 (4). Date of Electronic Publication: 2023 Feb 06.
DOI: 10.3390/jcm12041295
Abstrakt: Anti-dsDNA autoantibodies quantification and complement levels are widely used to monitor disease activity in systemic lupus erythematosus (SLE). However, better biomarkers are still needed. We hypothesised whether the dsDNA antibody-secreting B-cells could be a complementary biomarker in disease activity and prognosis of SLE patients. Fifty-two SLE patients were enrolled and followed for up to 12 months. Additionally, 39 controls were included. An activity cut-off (comparing active and non-active patients according to clinical SLEDAI-2K) was established for SLE-ELISpot, chemiluminescence and Crithidia luciliae indirect immunofluorescence tests (≥11.24, ≥374.1 and ≥1, respectively). Assays performances together with complement status were compared regarding major organ involvement at the inclusion and flare-up risk prediction after follow-up. SLE-ELISpot showed the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and, after follow-up, with an increased hazard ratio for disease flare-up (3.4) and especially renal flare (6.5). Additionally, the combination of hypocomplementemia and high SLE-ELISpot results increased those risks up to 5.2 and 32.9, respectively. SLE-ELISpot offers complementary information to anti-dsDNA autoantibodies to evaluate the risk of a flare-up in the following year. In some cases, adding SLE-ELISpot to the current follow-up protocol for SLE patients can improve clinicians' personalised care decisions.
Competing Interests: The authors declare that there is no conflict of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje